For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said.
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/K...
Fuente : http://feeds.sciencedaily.com/~r/sciencedaily/~3/K...